These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 17977962)

  • 1. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137).
    Shimura K; Kodama E; Sakagami Y; Matsuzaki Y; Watanabe W; Yamataka K; Watanabe Y; Ohata Y; Doi S; Sato M; Kano M; Ikeda S; Matsuoka M
    J Virol; 2008 Jan; 82(2):764-74. PubMed ID: 17977962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
    Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
    J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.
    Hassounah SA; Liu Y; Quashie PK; Oliveira M; Moisi D; Brenner BG; Sandstrom PA; Mesplède T; Wainberg MA
    J Virol; 2015 Dec; 89(23):12002-13. PubMed ID: 26378179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.
    Abram ME; Hluhanich RM; Goodman DD; Andreatta KN; Margot NA; Ye L; Niedziela-Majka A; Barnes TL; Novikov N; Chen X; Svarovskaia ES; McColl DJ; White KL; Miller MD
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2654-63. PubMed ID: 23529738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
    Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
    Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.
    Hassounah SA; Mesplède T; Quashie PK; Oliveira M; Sandstrom PA; Wainberg MA
    J Virol; 2014 Sep; 88(17):9683-92. PubMed ID: 24920794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro.
    Andreatta K; Miller MD; White KL
    J Acquir Immune Defic Syndr; 2013 Apr; 62(4):367-74. PubMed ID: 23187937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors.
    Goethals O; Clayton R; Van Ginderen M; Vereycken I; Wagemans E; Geluykens P; Dockx K; Strijbos R; Smits V; Vos A; Meersseman G; Jochmans D; Vermeire K; Schols D; Hallenberger S; Hertogs K
    J Virol; 2008 Nov; 82(21):10366-74. PubMed ID: 18715920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
    J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Elvitegravir Nanoformulation Crosses the Blood-Brain Barrier and Suppresses HIV-1 Replication in Microglia.
    Gong Y; Zhi K; Nagesh PKB; Sinha N; Chowdhury P; Chen H; Gorantla S; Yallapu MM; Kumar S
    Viruses; 2020 May; 12(5):. PubMed ID: 32443728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
    Hassounah SA; Alikhani A; Oliveira M; Bharaj S; Ibanescu RI; Osman N; Xu HT; Brenner BG; Mesplède T; Wainberg MA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
    Tsiang M; Jones GS; Goldsmith J; Mulato A; Hansen D; Kan E; Tsai L; Bam RA; Stepan G; Stray KM; Niedziela-Majka A; Yant SR; Yu H; Kukolj G; Cihlar T; Lazerwith SE; White KL; Jin H
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7086-7097. PubMed ID: 27645238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
    Roquebert B; Damond F; Collin G; Matheron S; Peytavin G; Bénard A; Campa P; Chêne G; Brun-Vézinet F; Descamps D;
    J Antimicrob Chemother; 2008 Nov; 62(5):914-20. PubMed ID: 18718922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
    Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.
    Marinello J; Marchand C; Mott BT; Bain A; Thomas CJ; Pommier Y
    Biochemistry; 2008 Sep; 47(36):9345-54. PubMed ID: 18702518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.
    Andreatta KN; Miller MD; White KL
    Antimicrob Agents Chemother; 2016 Feb; 60(2):757-65. PubMed ID: 26574015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.
    Andreatta KN; Goodman DD; Miller MD; White KL
    Antimicrob Agents Chemother; 2015; 59(6):3441-9. PubMed ID: 25824231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
    Ptak RG; Gentry BG; Hartman TL; Watson KM; Osterling MC; Buckheit RW; Townsend LB; Drach JC
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1512-9. PubMed ID: 20086149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.
    Oliveira M; Mesplède T; Moïsi D; Ibanescu RI; Brenner B; Wainberg MA
    AIDS; 2015 Nov; 29(17):2255-60. PubMed ID: 26372484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.
    Smith RA; Raugi DN; Pan C; Coyne M; Hernandez A; Church B; Parker K; Mullins JI; Sow PS; Gottlieb GS;
    PLoS One; 2012; 7(9):e45372. PubMed ID: 23028968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.